Luminal Iron Levels Govern Intestinal Tumorigenesis after Apc Loss In Vivo  by Radulescu, Sorina et al.
Cell Reports
ArticleLuminal Iron Levels Govern
Intestinal Tumorigenesis
after Apc Loss In Vivo
Sorina Radulescu,1 Matthew J. Brookes,2 Pedro Salgueiro,1 Rachel A. Ridgway,1 Ewan McGhee,1 Kurt Anderson,1
Samuel J. Ford,2 Daniel H. Stones,2 Tariq H. Iqbal,2 Chris Tselepis,2,* and Owen J. Sansom1,*
1Beatson Institute of Cancer Research, Glasgow, G61 1BD, UK
2Birmingham Cancer Research UK Centre, School of Cancer Sciences, University of Birmingham B15 2TH, UK
*Correspondence: c.tselepis@bham.ac.uk (C.T.), o.sansom@beatson.gla.ac.uk (O.J.S.)
http://dx.doi.org/10.1016/j.celrep.2012.07.003SUMMARY
It is clear from epidemiological studies that excess
iron is associated with increased risk of colorectal
cancer; however, questions regarding the mecha-
nism of how iron increases cancer risk, the source
of the excess iron (circulating or luminal), and
whether iron reduction represents a potential
therapeutic option remain unanswered. In this study,
we show that after Apc deletion, the cellular iron
acquisition proteins TfR1 and DMT1 are rapidly
induced. Conversely, restoration of APC reduces
cellular iron due to repression of these proteins. To
test the functional importance of these findings, we
performed in vivo investigations of the impact of iron
levels on intestinal tumorigenesis. Strikingly, deple-
tion of luminal (but not systemic) iron strongly sup-
pressed murine intestinal tumorigenesis, whereas
increased luminal iron strongly promoted tumori-
genesis. Taken together, our data definitively delin-
eate iron as a potent modifier of intestinal tumori-
genesis and have important implications for dietary
iron supplementation in patients at high risk of
colorectal cancer.INTRODUCTION
The Apc (adenomatous polyposis coli) gene is the most
commonly mutated tumor suppressor gene in sporadic colo-
rectal cancer (CRC; Bienz and Clevers, 2000). Loss of the APC
protein prevents the turnover of b-catenin, and hence b-catenin
accumulates in the nucleus and causes the activation of TCF/
LEF or Wnt target genes such as c-Myc and Cyclin D2 (Bienz
and Clevers, 2000). Of importance, APC loss appears to initiate
CRC, and thus one would predict that agents that can determine
the survival of APC-deficient cells could potently modify tumor
risk. In this context, a number of epidemiological studies have
shown that dietary factors can alter CRC risk (World Cancer
Research Fund / American Institute for Cancer Research,
2011). However, whether these agents target APC-deficient270 Cell Reports 2, 270–282, August 30, 2012 ª2012 The Authorscells over normal cells, as well as their mechanism of action, is
still unclear.
Iron is essential for all organisms, and iron-containing proteins
catalyze a variety of crucial metabolic processes, such as
oxidative phosphorylation and DNA synthesis, as well as cell-
cycle progression and growth (Le and Richardson, 2002). In
addition, excess iron can mediate reactive oxygen species
through Fenton reaction chemistry, resulting in lipid, protein,
and DNA damage (Toyokuni, 1996). A link between excess iron
and cancer incidence in CRC has been reported (Chua et al.,
2010; Kato et al., 1999; Lee et al., 2004; Mainous et al., 2005;
Nelson, 2001; Toyokuni, 2009; Weinberg, 1994, 1996). Most
notably, a meta-analysis of 33 epidemiological studies showed
that 75% of studies supported an association between excess
iron and CRC risk (Nelson, 2001). This is supported by the obser-
vation that patients with hemochromatosis (HFE) mutations,
associated with the iron overload disorder hereditary hemochro-
matosis, have an increased risk of not only hepatocellular carci-
noma but also CRC (Nelson et al., 1995; Shaheen et al., 2003).
Conversely, several human epidemiological studies showed
that a decrease in total body iron levels resulting from blood
withdrawal decreases the risk of various cancers, including
CRC (Edgren et al., 2008; Zacharski et al., 2008). However,
despite this close association with tumorigenesis and disease,
the role of iron in sporadic carcinogenesis and the mechanism
by which it acts are still unclear. In particular, whether iron levels
are a cause or a side effect of tumorigenesis has yet to be
established, with previous studies in animal models reporting
conflicting evidence regarding the impact of iron on colon cells
(Lund et al., 1998; Soyars and Fischer, 1998).
Our own previous studies demonstrated that stimulating
colorectal cell lineages with iron results in amplification of Wnt
signaling (Brookes et al., 2008), the major oncogenic signaling
pathway in the colon (Bienz and Clevers, 2000). Of importance,
though, iron could only amplify Wnt signaling in the background
of a loss of the tumor suppressor APC. These observations
were further supported by a more recent study that highlighted
a class of iron chelators (acyl hydrazones) as inhibitors of Wnt
signaling and cell growth (Song et al., 2011). Furthermore, we
previously reported a modulation in the expression of iron trans-
port proteins in the malignant progression of disease (Brookes
et al., 2006; Ward et al., 2008). In particular, in the process of
human CRC, there was increased expression of the cellular iron
Figure 1. Effect of Modulating Wnt
Signaling on Expression of Iron Transport
Proteins
(A) Culturing RKO cells with iron (IL) for 24 hr
repressed TfR1 and DMT1, and increased ferritin
protein levels. LiCl treatment increased the level of
TfR1, DMT1, and c-Myc expression relative to
control. Costimulation with LiCl and IL (IL+LiCl)
further increased c-MYC, TfR1, and DMT1 levels
and suppressed ferritin expression. p < 0.0001
c-MYC, DMT1, p = 0.0071 TfR1 in IL+LiCl versus IL
alone; p = 0.003 c-MYC, p = 0.0017 TfR1,
p = 0.0007 DMT1 in IL+LiCl versus LiCl alone,
Student’s t test; * denotes statistical significance
compared with control; y denotes statistical
significance compared with LiCl alone. b-actin
was used for protein normalization. Data are pre-
sented as mean ± SEM.
(B) To assess cellular IL levels, a ferrozine assay
was performed in RKO cells in control or in the
presence of IL or LiCl, or both (IL+LiCl) for 24 hr.
Wnt activation further increases IL content
(p < 0.0001 IL+LiCl versus LiCl alone, p = 0.0006
IL+LiCl versus IL alone, Student’s t test;
* denotes statistical significance compared with
control; y denotes statistical significance com-
pared with LiCl alone). Data are presented as
mean ± SEM.
(C) Culturing SW480 cells for 24 hr with IL
resulted in upregulation of c-MYC, TfR1, and
DMT1, and repression of ferritin. Reconstitution
of WT human Apc and culture with IL (IL+APC)
significantly reduced c-MYC, TfR1 and DMT1 and
ferritin expression (p = 0.002 TfR1, p = 0.003
DMT1, p < 0.0001 ferritin IL+APC versus IL,
Student’s t test; * denotes statistical significance
compared with control). Data are presented as
mean ± SEM.
(D) SW480 cells reconstituted with WT human
APC resulted in significantly decreased cellular IL
content (ferrozine assay; control+APC versus
control, p = 0.0053; control+APC versus IL +APC,
p < 0.0048, Student’s t test; * denotes statistical
significance compared with control; y denotes
statistical significance compared with IL alone).
Data are presented as mean ± SEM.
(E) To assess the association of c-MYC with TfR1, DMT1, and ferritin in vivo, mRNA expression levels were assessed in eight murine polyps from individual
ApcMin/+ mice, 20 human colonic polyps, and 10 human colorectal carcinomas. Expression levels were assessed relative to matched normal control mucosa.import proteins (transferrin receptor 1 (TfR1) and divalent metal
transporter 1 (DMT1), and a loss of cellular iron export function.
Although both the epidemiological evidence and results from
our human cell linemechanistic studies are suggestive of a direct
role of iron in CRC, it should be remembered that 25% of epide-
miological studies have failed to find a link with iron consump-
tion, and the increase in relative risk, although significant, is
small. Thus, it is vital to test for a direct role of iron in sporadic
carcinogenesis in vivo. In this study, we investigate how iron
modulation affects intestinal tumorigenesis following Apc loss
in vivo. Of importance, we show that the precise levels of iron
dictate the proliferation and survival of Apc-deficient cells. This
directly translates to suppressed tumorigenesis when luminal
iron is depleted, and to increased tumorigenesis when luminal
iron is in excess.RESULTS
Modulation of IronTransport Proteins as aConsequence
of Wnt Signaling
To ascertain whether the expression of the iron import proteins
TfR1 and DMT1, and the iron storage protein ferritin are modu-
lated as a consequence of Wnt signaling, we selected and
cultured two cell lines, RKO and SW480, in the presence and
absence of iron. These two lines were chosen because they
contain wild-type (WT) and mutant Apc, respectively. By
activating Wnt signaling [via GSK3b inhibition using lithium
chloride (LiCl)] in RKO cells, a 3-fold c-MYC induction was also
associated with significant increases in TfR1 (mean 1.8-fold,
p = 0.021) and DMT1 (mean 1.7-fold, p = 0.036) protein ex-
pression compared with control (Figure 1A). No change wasCell Reports 2, 270–282, August 30, 2012 ª2012 The Authors 271
observed for ferritin protein expression. Costimulation of cells
with the GSK3b inhibitor and iron further enhanced c-MYC,
TfR1, and DMT1 levels by at least one-third above either GSK3
inhibitor or iron alone (p < 0.0001 c-MYC, DMT1; p = 0.0071
TfR1 in iron+LiCl versus iron alone; p = 0.003 c-MYC; p =
0.0017 TfR1; p = 0.0007 DMT1 in iron+LiCl versus LiCl alone;
Figure 1A). Conversely, ferritin protein expression was statisti-
cally repressed by half ormore comparedwith either GSK3 inhib-
itor (p = 0.013) or iron alone (p = 0.02). Of interest, without GSK3
inhibition, there was a dramatic decrease in TfR1 and DMT1
following treatment with iron, which was not observed following
the activation of Wnt signaling (p < 0.0001). This made an impor-
tant functional difference because when Wnt signaling was acti-
vated, the cells were now able to increase the expression of their
cellular iron import proteins. This was evidenced by increased
cellular iron deposition in cells challenged with iron and LiCl
compared with cells challenged with iron (mean 3-fold, p =
0.0003) or LiCl alone (mean 40-fold, p < 0.0001; Figure 1B). To
further solidify these observations, we performed a reverse set
of experiments inwhich theexpression of c-MYCand ironmetab-
olism proteins was assessed in SW480 cells (a cell line with de-
regulated Wnt signaling) before and after restoration of APC
(Figures 1C and 1D). We saw that challenging SW480 cells with
iron further deregulated Wnt signaling targets such as c-MYC
(mean 2.7-fold, p = 0.0004) and increased the expression of
TfR1 (mean 2.7-fold, p < 0.0001) and DMT1 (mean 2.3-fold,
p < 0.0001; Figure 1C). Functionally, this was associated with a
10-fold increase in cellular iron deposition (p < 0.0001; Figure 1D).
When APC was reconstituted, TfR1 (p = 0.002) and DMT1
(p = 0.003) were dramatically reduced bymore than half following
iron treatment (Figure 1C). In addition, the cellular iron levels in
SW480 cells with reconstituted APC (control+APC) were statisti-
cally decreased to one-fifth relative to sham transfected cells
(p = 0.0053) and also moderately decreased when cultured in
the presence of high iron (iron versus iron+APC, p = 0.0048;
Figure 1D). As previously reported (Brookes et al., 2008), the
iron-mediated induction of cellular proliferation was no longer
observed when WT APC was reconstituted into these cells.
Association of Wnt Signaling with TfR1, DMT1, and
Ferritin Expression
To further support the relationship between deregulated Wnt
signaling and the expression TfR1, DMT1, and ferritin, we
assessed the expression of c-Myc (a key target of canonical
Wnt signaling), TfR1, DMT1, and ferritin in ApcMin/+ mouse
polyps (n = 8), human polyps (n = 20), and human colorectal
carcinomas (n = 10), each matched with an adjacent nondi-
seased control mucosa (Figure 1E). The ApcMin/+ mouse model
carries a germline mutation in the Apc gene and mimics familial
adenomatous polyposis, a hereditary form of CRC (Su et al.,
1992). The mice develop multiple adenomas and hence repre-
sent an early stage of CRC. In all eightApcMin/+ adenomas exam-
ined, we observed a marked induction of c-Myc mRNA (8/8
mean fold induction of 4.58), TfR1 (7/8 mean fold increase of
2.6) and DMT1 mRNA (7/8 mean fold increase of 3.2) compared
with nondiseased adjacent tissue. A statistical analysis sug-
gested a robust correlation of c-Myc with TfR1 (p < 0.004) and
DMT1 (p < 0.001) expression; however, no relationship was272 Cell Reports 2, 270–282, August 30, 2012 ª2012 The Authorsobserved with ferritin, which was overexpressed in five of the
eight samples. Furthermore, this induction of c-Myc, TfR1, and
DMT1 was also observed in human adenomas (16/20, 16/20,
and 15/20, respectively) and carcinomas (10/10, 7/10, and
9/10, respectively). Ferritin mRNA was overexpressed in only
10/20 and 4/10 human adenomas and carcinomas, respectively.
Because previous studies have shown that c-MYC may regu-
late the expression of TfR1 by directly binding to its promoter
region, as well as by indirectly regulating the iron regulatory
protein 2 (IRP2) and ferritin, we overexpressed c-MYC in the
RKO cell line using the well-characterized c-MycER system
(Figure 2; Littlewood et al., 1995; O’Donnell et al., 2006; Wu
et al., 1999). c-MYC induction mediated by tamoxifen treatment
resulted in increased mRNA of TfR1 (mean 2.1-fold, p = 0.017)
and DMT1 (mean 1.9-fold, p = 0.0005), whereas ferritin pro-
tein expression was repressed compared with non-tamoxifen-
treated cells (p < 0.0001; Figures 2A–2D). Upon c-MYC activa-
tion in the presence of iron, an almost double cellular iron
acquisition was observed compared with non-tamoxifen-treated
cells challenged with iron (Figure 2E). To further confirm a direct
regulation of these proteins by c-MYC, we deleted c-MYC in
the adult murine intestine. To that end, we generated AHCre+
c-Mycfl/fl mice. The AH Cre transgene yields highly penetrant
Cre expression in the intestine following injection of beta-naph-
thoflavone and thus allows c-Myc to be inducibly deleted from
the adult intestine (de Alboran et al., 2001; Sansom et al.,
2007). Our previous studies showed that short-term deletion of
c-MYC does not affect intestinal homeostasis, and that Wnt
gene activation and the phenotypes of APC loss are dependent
on c-MYC activity (Sansom et al., 2004, 2007). While investi-
gating mRNA levels in vivo in WT versus c-Myc deleted intes-
tines, we noted a significant downregulation of DMT1 by almost
half (p = 0.0018) upon c-Myc loss. In contrast, TfR1 was not
affected upon c-Myc deletion alone, but was significantly
decreased to almost one-third in mice that had a combined defi-
ciency for APC and c-MYC when compared with APC-deficient
intestines alone (AHCre+ Apcfl/fl c-MYCfl/fl versus AHCre+ Apcfl/fl,
p = 0.02). Therefore, in vivo c-MYC levels are important for the
expression of components of the iron import machinery.
Iron Modifies Intestinal Tumorigenesis
Given these clear mechanistic links between Wnt signaling and
cellular iron protein machinery, and the upregulation of these
proteins in the very early stages of CRC carcinogenesis, we
next examined whether modifying the levels of iron could affect
intestinal tumorigenesis in vivo. To that end, we examined
whether a diet completely lacking iron [the iron-deficient diet
(IDD)] could suppress tumorigenesis, and a diet with excess
iron [the carbonyl iron diet (CID)] could stimulate tumorigenesis
in the ApcMin/+ mouse (Su et al., 1992). In this mouse model,
loss of the remaining WT Apc allele initiates tumorigenesis early
in life and the mice develop hundreds of adenomas throughout
their small intestine and colon by 100 days of age. ApcMin/+
mice were fed either an IDD (n = 16) or a control diet (CD;
n = 17) from weaning and were euthanized at 80 days of age
(Figures 3A–3C). We determined the tumor burden by assessing
tumor number and size from whole-mount intestines. ApcMin/+
mice fed the IDD developed a greatly reduced tumor burden
Figure 2. Effect of c-Myc Overexpression
on Cellular Iron Metabolism
RKO cells were transiently transfected with either
pCDNA3.1/Zeo-MYCER or empty vector, and the
chimeric protein was then activated by the addition
of 4-OHT.
(A) Representative western blot demonstrating the
expression of the chimeric protein.
(B) c-MYC overexpression resulted in increased
TfR1 andDMT1mRNA expression (p = 0.017 TfR1,
p = 0.0005 DMT1, Student’s t test). Data are
presented as mean ± SEM.
(C) Representative western blot indicating ex-
pression levels of TfR1, DMT1, and ferritin in
control and c-MYC overexpressing cells. B-actin
was employed for protein normalization.
(D) c-MYC overexpression resulted in increased
TfR1 and DMT1, and decreased ferritin protein
expression (p = 0.0025 TfR1, p = 0.046 DMT1,
p < 0.0001 ferritin, Student’s t test). Data are
presented as mean ± SEM.
(E) To assess the influence of activated c-MYC
ER on cellular iron (IL) levels, cells were cultured in
the presence and absence of 4-OHT and IL.
Activated c-MYC ER and IL (c-Myc ER+4-OHT+IL)
enhanced cellular IL loading compared with cells
with no IL (c-Myc ER+4-OHT) and in nonactivated
c-MYC ER cells challenged with IL (c-Myc ER+IL;
p < 0.0001 c-Myc ER+4-OHT+IL versus c-Myc
ER+4-OHT, p = 0.0016 c-Myc ER+4-OHT+IL
versus c-Myc ER+IL, Student’s t test). Data are
presented as mean ± SEM; * denotes statistical
significance compared with control; y denotes
statistical significance compared with c-Myc
ER+IL.by more than half (p < 0.0001), with a marked reduction in both
tumor number (p < 0.0001) and size (p = 0.0006). WT mice
treated with the IDD remained healthy and showed no intestinal
phenotypes within the time course of the experiment. Further-
more, ApcMin/+ mice on the IDD were healthy and gained weight
at the same rates as controls (Figure S1). In contrast, mice fed an
iron-rich diet (CID; 2%carbonyl ironw/w; n = 13) rapidly began to
show signs of intestinal neoplasia and thus had to be harvested
at 60 days of age (Figures 3D and 3E). Due to the rapid develop-
ment of intestinal tumorigenesis and the resulting ill health of the
mice, we assessed tumor burden by scoring tissue sections for
the number of tumors present within the first 10 cm of the small
intestine. The CID resulted in a 2- to 3-fold amplification in tumor-
igenesis compared with mice on the CD sacrificed at the same
60-day time point (p = 0.002; Figure 3D). Overall, the 2%
carbonyl iron resulted in higher levels of iron in both normal intes-
tine and adenomas compared with the CD, as detected by Perls’
Prussian staining (Figure 3F; Figure S2). Of importance, previous
reports indicate that in the short term, this level of dietary iron
overload is not enough to cause liver toxicity, which suggests
that the ill heath was due to the formation of multiple intestinal
adenomas (Pigeon et al., 1999).
Given that tumor formation in the ApcMin/+ mice occurred
following loss of the remaining Apc allele, it is possible that
iron affects both tumor growth and initiation by increasing themutation rates of the WT allele. Therefore, we next assessed
whether the IDD and CID could modify tumorigenesis following
the loss of both copies of Apc. For these studies we used the
Lgr5creERT2+ Apcfl/fl model, which has Apc deletion solely in
stem cells (Barker et al., 2007). This represents a rapid model
of intestinal tumorigenesis, with mice developing numerous
adenomas within 50 days following Cre induction. Lgr5creERT2+
Apcfl/flmice were placed on IDD (n = 18), CID (n = 17), or CD (n =
24), and following a 2-week dietary acclimatization were treated
with tamoxifen to induce Cre-mediated recombination of Apc
and allowed to age until signs of ill health were observed (Fig-
ure 4A). In this potent model of intestinal tumorigenesis, IDD
strongly attenuated tumorigenesis, as indicated by the extended
survival of mice on the IDD compared with the CD (median
survival 89 days (IDD) versus 61 days (CD), p = 0.001, Kaplan
Meier method, logrank). Again, the IDD did not have any adverse
effects on the health of the mice as assessed by weight moni-
toring (Figure S3). Conversely, mice on the CID had a dramati-
cally shortened survival period compared with mice on the CD
(median survival 42 days (CID) versus 61 days (CD), p = 0.001,
Kaplan Meier method, logrank).
To confirm that the cause of ill health in the CID group was due
to increased tumorigenesis, we next performed a time-point
experiment soon after Cre induction. For this experiment we
again used the Lgr5creERT2+ Apcfl/fl mice, but this timeCell Reports 2, 270–282, August 30, 2012 ª2012 The Authors 273
Figure 3. Iron Modifies Intestinal Tumori-
genesis in the ApcMIN/+ Mouse
(A–C) Tumor number, size, and burden compar-
ison between CD- and IDD-fed mice at 80 days of
age (p < 0.0001 number, burden, p = 0.0006 size,
Mann-Whitney).
(D) Tumor number comparison on section (first
10 cm of intestine) between CD- and CID-fed mice
at 60 days of age (p = 0.002, Mann-Whitney).
(E) Representative H&E pictures of intestines from
CD- and CID-fed mice. Panels highlight numerous
small adenomas in the CID-fed mice. Scale bar:
200 mm.
(F) Perls’ Prussian blue staining of adenomas from
control and CID-fed mice showing iron deposits
within the CID tumors. Scale bar: 10 mm. See also
Figures S1 and S2.administered a higher induction regime (four injections of tamox-
ifen over 4 days) to obtain more incipient adenomas, and took
them at an early time point (day 15 post induction). At this stage,
themice on the CD (n = 3) had small lesions in the intestine visible
on section but were otherwise without a phenotype. In contrast,
the mice on the CID (n = 3) were already displaying signs of ill
health at the same time point (day 15) and upon harvesting,
they presented a thickened intestine, a hallmark of multiple
adenomas. Figures 4B–4D show that the CID led to a drastic
increase in both number and size at this early time point
(p = 0.04). These lesions also show marked iron deposits in
enterocytes, as detected by Perls’ Prussian staining, in contrast
to CD lesions, in which such deposits are absent (Figure S3).
The Lgr5creERT2+ construct contains a green fluorescent
protein (GFP) reporter knocked into the endogenous leucine-
rich repeat containing a G protein-coupled receptor 5 (Lgr5)
locus, which allows visualization of cells that express Lgr5
(Barker et al., 2007). Elegant studies by Merlos-Sua´rez et al.274 Cell Reports 2, 270–282, August 30, 2012 ª2012 The Authors(2011) and van der Flier et al. (2007,
2009) showed that Lgr5 marks a stem
cell population in the normal intestine
that is retained within adenomas, and
thismay reflect a cancer stemcell popula-
tion. A detailed characterization of the
Lgr5-GFP population showed that this
marks a particular subset of Wnt target
genes that define the stem cell popula-
tion. Therefore, examination of GFP
expression may allow assessment of the
Wnt stem cell gene expression, which is
pertinent given our previous in vitro
studies linking iron to activating Wnt
signaling (de Lau et al., 2011). When
we examined whole-mount intestines for
the levels of GFP expression in the
Lgr5creERT2+ Apcfl/fl mice on the CID,
we noticed a marked increase compared
withmiceon theCD (Figure 4E). To assess
whether this was specific to intestinal
cells with modifications in the Wntpathway, we crossed the ApcMin/+ mice with Lgr5creERT2+
mice. By using the GFP reporter in these mice, we were able to
assess Lgr5 expression using multiphoton microscopy to create
a 3D reconstruction of the intestinal crypts. In the normal epithe-
lium, cells positive for GFP expression (and hence Lgr5 expres-
sion) are located at the bottom of the crypt. Of importance, we
found a significant 1.5- to 2-fold increase in the area occupied
by Lgr5-positive intestinal stem cells in mice carrying the
ApcMin/+ allele (Figure 4F; Figure S4). This was in contrast to
Lgr5creERT2+ Apc+/+ mice on the CID, which had the same
volume of Lgr5 intestinal stem cells as mice on the CD. This
demonstrates once more that iron sensitivity is strictly related
to Apc status both in vivo and in vitro.
Iron Levels Govern the Cellular Fate of Apc-Deficient
Cells
After determining that iron levels were potently modifying
tumorigenesis, we next wanted to investigate the direct impact
Figure 4. High Iron Drives Intestinal Tumor-
igenesis and Lgr5 Expression
(A) Kaplan-Meier survival plot for Lgr5creERT2+
Apcfl/flmice on IDD, CD, or CID (p = 0.001, logrank,
IDD versus CD, and CID versus CD).
(B) Percentage of crypts with lesions (in intestines
from Lgr5creERT2+ Apcfl/fl mice on CD or CID at
day 15 post-induction. A lesion was defined as
a clump of >10 cells with nuclear b-catenin accu-
mulation. Each individual crypt (from a strip of
10 cm of intestine) was assessed for the presence
or absence of a lesion (p = 0.04, Mann-Whitney).
(C) The average number of cells displaying nuclear
b-catenin per lesion (as a measure of size) in
intestines from Lgr5creERT2+ Apcfl/fl mice on
control or CID at day 15 post-induction (p = 0.04,
Mann-Whitney).
(D) Representative H&E pictures of intestines from
Lgr5creERT2+ Apcfl/flCD- andCID-fedmice at day
15 post-induction. Red lines highlight the size of
the Apc-deficient crypts. Scale bar: 10 mm.
(E) In vivo GFP fluorescence imaging of whole-
mount intestines from Lgr5creERT2+ Apcfl/fl mice
on CD or CID (end of tumorigenesis). Tumors
express GFP.
(F) Measurement of Lgr5 cell volume, via the GFP
label, in vivo in normal crypts using a multiphoton
laser microscope. MIN CID: Lgr5creERT2+
ApcMIN/+ on high iron for 2 weeks. WT CID:
Lgr5creERT2+ Apc+/+ littermate on high iron for
2 weeks. WT control: Lgr5creERT2+ Apc+/+ on CD
(age matched). A minimum of 60 crypts were
measured per mouse (MIN CID versusWTCID, p <
0.0001, Mann-Whitney). Error bars represent
standard deviation (SD).
See also Figures S3 and S4.of iron on intestinal enterocytes that have acutely lost both copies
of the Apc gene. To that end, we generated AHCre+ Apc fl/flmice
and studied the impact of iron modulation 4 days after Apc gene
deletion (Sansom et al., 2004). Mice were placed on the IDD (n =
5), CID (n = 3), or CD (n = 5) for 2 weeks before induction. Figures
5A–5C show that the CID increased proliferation rates by 4- to 5-
fold following Apc loss (p = 0.015), whereas the IDD promoted
a marked increase in apoptosis by 2- to 3-fold (p = 0.015). This
is in good agreement with the tumor burden outcomes obtained
earlier in ApcMin/+ mice for the two diets, i.e., an increase in
apoptosis gave rise to slow-growing, small tumors in mice on
the IDD, whereas an increase in proliferation resulted in larger,
more aggressive tumors in mice on the CID. We also looked at
the effect of both diets onWT intestines (Figure S5), andwenoted
no change in the mitotic or apoptotic index for animals on the
CID, but an increase in both mitosis and apoptosis in mice on
the IDD. However, this increase in both apoptosis and mitosis
did not alter the crypt size (compared with CD), indicating that
WT intestines are able to copewith the lack of iron bymaintaining
a careful balance between proliferation and death. We also care-
fully monitored the health and potential anemia of the mice on
the IDD by weighing the mice and obtaining blood cell counts
at the end of the experiment (Figures S5 and S6).We then scored apoptosis and mitosis in the tumors from
Lgr5creERT2+ Apcfl/fl survival cohorts to see if these effects on
proliferation and apoptosis were retained throughout tumorigen-
esis. Figures 5D–5F show that adenomas from the iron-deficient
mice still retained a higher level of apoptosis (p = 0.006), and the
tumors that developed on the CID had overall more proliferation
(p = 0.006). Thus, the levels of iron directly affect the ability of
Apc-deficient cells to survive and proliferate both immediately
following Apc loss and within adenomas.
To confirm our in vitro results showing that Apc-deficient cells
had high levels of TfR1 andDMT1 in vivo, and that thesewere not
downregulated following iron administration, we examined the
mRNA levels by quantitative reverse transcriptase (qRT)-PCR.
In order to isolate a purer intestinal cell population, we used
the laser capture microdissection (LCM) technique, which
enabled us to microdissect specific parts of the intestinal crypt
villus structure and thus enrich in the epithelial cells of choice
(Potter and Brunskill, 2012). We found that mice on the CID
had dramatically increased levels of TfR1, DMT1, and ferritin
following Apc gene deletion compared with WT mice on the
same diet (Figure S7). Moreover, to further examine whether
there was an additional expansion of the intestinal stem cell
(ISC) signature following Apc loss, we looked specifically at theCell Reports 2, 270–282, August 30, 2012 ª2012 The Authors 275
Figure 5. Iron Levels Modulate Proliferation and Apoptosis Immediately after Apc Loss In Vivo
(A) Mitotic index as percentage of cells in mitosis per crypt in Apc-deficient enterocytes from AHCre+ Apc fl/fl mice on CD, IDD, or CID at day 4 post-induction
(p = 0.015, CID versus CD, and CID versus IDD, Mann-Whitney).
(B) Apoptotic index as percentage of cells in apoptosis per crypt in Apc-deficient enterocytes from AHCre+ Apc fl/fl mice on CD, IDD, or CID at day 4
post-induction (p = 0.015, IDD versus CD, and IDD versus CID, Mann-Whitney).
(C) Representative H&E pictures of intestines from AHCre+ Apcfl/fl mice on CD, IDD, or CID at day 4 post-induction. Arrows indicate apoptotic bodies. Circles
indicate mitotic figures. Scale bar: 10 mm.
(D) Representative H&E pictures of adenomas from Lgr5creERT2+ Apcfl/flmice on CD, IDD, or CID at endpoint tumorigenesis. Arrows indicate apoptotic bodies.
Circles indicate mitotic figures. Scale bar: 10 mm.
(E) Mitotic index as percentage of cells in mitosis per adenoma in Lgr5creERT2+ Apcfl/flmice on CD, IDD, or CID at endpoint tumorigenesis (p = 0.006, CID versus
CD, and CID versus IDD, Mann-Whitney).
(F) Apoptotic index as percentage of cells in apoptosis per adenoma in Lgr5creERT2+ Apcfl/flmice on CD, IDD, or CID at endpoint tumorigenesis (p = 0.006, IDD
versus CD, and IDD versus CID, Mann-Whitney). See also Figures S5 and S6.
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Figure 6. High Iron Levels Alter Stem Cell
Gene Expression following Apc Loss In Vivo
A population of cells highly enriched in intestinal
stem cells was obtained by LCM of the bottom half
of the intestinal crypt in WT and Apc-deficient
mice (day 4 post-induction). A second population
of cells was isolated away from the stem cell zone
but still within the recombined area of the crypt
and villus, representing the non-stem-cell zone.
qRT-PCR analysis of the expression of a panel of
stem cell and Wnt target genes was performed in
these stem-cell-enriched and non-stem-cell-zone
populations.
(A) mRNA levels of stem cell genes Olfm4, Lgr5,
Troy, and Rgmb (left panel), as well as Wnt target
genes Cyclin D2, c-Myc, and Axin2 (right panel),
are all increased following Apc loss in mice on
the CID compared with WT mice on the same diet
(p < 0.01).
(B) mRNA levels of stem cell genes Olfm4, Lgr5,
Troy, and Rgmb are increased in the stem cell
compartment of Apc-deficient mice on the CID
compared with CD (left panel, p < 0.01). There
is no difference in the expression of these stem
cell genes in the non-stem cell compartment
between diets.
(C) mRNA levels of Wnt target genes Cyclin D2,
c-Myc, and Axin2 are increased in both the stem
cell compartment (left panel) and the non-stem
cell compartment (right panel) of Apc-deficient
mice on the CID compared with CD (p < 0.01). See
also Figure S7.stem cell compartment (bottom of the crypt) for the expression
levels of the ISC signature genes olfactomedin 4 (Olmf4), Lgr5,
tumor necrosis factor receptor superfamily member 19 (Troy)
and RGM domain family member B (Rgmb; van der Flier et al.,
2009). These genes were all significantly upregulated in Apc-
deficient mice treated with high iron compared with WT mice
on the same diet (Figure 6A). To verify that this was not simply
a reflection of an increased ISC signature following Wnt activa-
tion (via Apc loss), we compared the expression in CID versus
CD within the same stem/progenitor cell zone. Our results
show that there was a significant increase in the ISC targets in
the iron-treated mice. This was specific to the crypt base, as
LCM of the top of the crypt did not show an increase in stem
cell genes even though these cells are also Apc-deficient (Fig-
ure 6B). However, Wnt target genes such as c-Myc, Axin2, and
Cyclin D2 were upregulated in both the crypt base and the topCell Reports 2, 270–282of the crypt in the CID group, which is
consistent with Wnt pathway activation
throughout the crypt and villus
(Figure 6C).
Delineating the Pool of Iron that Is
Responsible for Rescuing
Tumorigenesis
Although our data clearly demonstrate
a role for iron in tumorigenesis, they fail
to delineate the pool of iron, as one would
expect that feeding an IDDwould result in decreased luminal iron
levels and also chronically mediate a systemic iron deficiency.
Thus, in an attempt to separate these two pools of iron, Apc-
Min/+ mice were fed an IDD but maintained systemically iron
replete (IDD+IDex) by subcutaneous injections of iron dextran
(IDex; Theurl et al., 2005). Briefly, ApcMin/+ mice were put on
the IDD at weaning and given two subcutaneous injections of
50mg IDex on two consecutive days to reach systemic iron over-
load. The iron load status was maintained with an additional
subcutaneous injection of 50 mg IDex each month. The results
of these studies again demonstrate a suppressed tumor burden
compared with mice on the CD (p = 0.004; Figures 7A–7C).
Furthermore, Perls’ Prussian blue staining of the intestines
from IDD+IDex-treated mice does not show intestinal iron
deposits, in contrast to mice on the CID, highlighting the fact
that systemic iron overload does not lead to iron accumulation, August 30, 2012 ª2012 The Authors 277
Figure 7. The Luminal Iron Pool Is Responsible for Intestinal Tumor Formation In Vivo
(A–C) Tumor number, size, and burden comparison between CD, IDD, and IDD+IDex treatment (IDD+IDex) ApcMIN/+ mice at 80 days of age. Systemic iron
overload via IDex treatment does not affect the tumor protection conferred by the lack of dietary iron.
(D) Tumor burden comparison between ApcMIN/+ mice with systemic iron overload (IDex), systemic iron chelation (DFO), or CD alone (CD).
(E) Overview representing the therapeutic opportunity offered by dietary iron modulation.in intestinal tissue (Figure S2). However, these observations do
not rule out the possibility that the systemic injections of IDex
could have had an impact on tumorigenesis, so we further278 Cell Reports 2, 270–282, August 30, 2012 ª2012 The Authorstreated a separate cohort of ApcMin/+ mice (n = 9), this time
on a CD, and administered IDex as before. We failed to observe
any influence on tumor burden at 80 days (Figure 7D).
Furthermore, decreasing the level of systemic iron in ApcMin/+
mice (n = 8) by administering daily injections of a potent iron
chelator, desferrioxamine (DFO), also failed to affect tumorigen-
esis. Taken together, these data suggest that the systemic iron
pool has little effect on intestinal tumorigenesis, but luminal
iron is crucial.
DISCUSSION
In this study, we show that spontaneous intestinal neoplasia
driven by the loss of the key intestinal tumor suppressor Apc is
highly dependent on iron. Moreover, we demonstrate that an
excess of iron promotes intestinal tumorigenesis, and that
tumorigenesis was markedly suppressed in mice fed an IDD.
Our observations provide an explanation for previous results
from human epidemiological studies that point to high dietary
iron intake as a risk factor for tumorigenesis (Kato et al., 1999;
Lee et al., 2004; Mainous et al., 2005; Nelson, 2001; Nelson
et al., 1995; Shaheen et al., 2003; Weinberg, 1994). In addition
to demonstrating that iron excess drives tumorigenesis in
the background of an aberration in Apc, we also identified the
luminal iron pool (rather than the circulating iron pool) as the
major driver of carcinogenesis.
One of the most exciting findings from our studies is that
Apc-deficient cells appear to require precise levels of iron for
efficient tumorigenesis in vivo. Removal of iron drives apoptosis
of Apc-deficient cells, and raising the levels of iron increases
proliferation, which suggests that levels of iron are critical for
the cellular fate following Apc loss. By altering the outcome of
an Apc mutation, one would predict that this could account for
changes in the lifetime risk of iron exposure. Of importance,
our studies investigating the impact of iron on WT intestinal
enterocytes showed that even very high levels of iron did not
lead to spontaneous tumorigenesis. Therefore, it is the impact
of iron on cells that have deregulatedWnt signaling that is crucial.
This is consistent with our in vitro data showing that down-
regulation of Wnt signaling (through APC addition) alters the
proliferation of CRC cell lines, and our in vivo data showing
deregulation of iron import proteins at the early stages of
adenoma formation in both humans and mice. In support of the
importance of a link among Wnt signaling, iron, and colorectal
neoplasia, a recent study showed that a class of iron chelators,
acyl hydrazones, abrogate Wnt signaling and growth of CRC
cell lines with constitutive Wnt signaling (Song et al., 2011).
In the context of human CRC, one issue that has been
difficult to resolve is the particular genotype–phenotype rela-
tionship of the sporadic Apc mutations that occur. Rather
than a complete loss-of-function mutation in the Apc gene,
specific mutations leading to a truncated protein that can
bind b-catenin but not Axin may occur. These mutant proteins
still cannot turn over b-catenin, but may still be able to more
subtly modulate Wnt signaling activity. Knockin of the common
human mutation Apc1322T in the mouse leads to faster tumori-
genesis than the ApcMin/+ mutation (Pollard et al., 2009). Wnt
target gene activation in the model is modestly altered with
a reduction in many Wnt targets but an increase in Lgr5 and
other stem cell markers (Lewis et al., 2010). Given the
increased levels of Lgr5 we observed in ApcMin/+ mice followingiron treatment, it is tempting to speculate that one of the mech-
anisms by which iron may increase the lifetime risk of CRC is to
increase the number of stem cells that carry a single Apc muta-
tion. These cells could then act as highly efficient cells of origin
for intestinal cancer, and hence increase the number of target
cells for transformation. Indeed, we found that Apc loss
combined with a CID upregulated the stem cell signature in
the stem cell zone.
However, in addition to iron fueling Wnt signaling and other
cellular processes, such as DNA synthesis, iron also likely
contributes to increased free-radical-mediated cellular damage
(e.g., lipid peroxidation and DNA damage) due to its propen-
sity to be involved in Fenton reaction chemistry (Toyokuni,
1996, 2009). Further studies to elucidate the precise contribution
of these factors to CRC initiation and progression will be of great
interest. For example, modulation of reactive oxygen species
levels was shown to have a considerable impact on intestinal
stem cell proliferation in Drosophila (Biteau et al., 2008), and
antioxidants are associated with protection against CRC.
Taken together, our data provide strong support for the notion
that luminal iron cooperates with Apc loss to promote intestinal
tumorigenesis, and that chelation of this pool of iron may
provide a platform for therapeutic intervention (Figure 7E) in
individuals at high risk of developing CRC (e.g., individuals
with colorectal adenomas and inflammatory bowel disease).
Individuals with these conditions commonly present with
systemic anemia, and current practice is to treat such patients
with high doses of oral iron. According to our observations,
this is likely to both exacerbate their condition and elevate their
risk of developing CRC. Instead, we suggest that such patients
should be supplemented systemically with intravenous infusions
of iron and concurrently receive colonic luminal iron chelation
therapy. Such a protocol would resolve the anemia and at
the same time diminish the carcinogenic pool of iron residing
with the colon.
EXPERIMENTAL PROCEDURES
Ethics Statement
All mouse experiments were performed according to the UK Home
Office guidelines. The research was approved by the Glasgow University
Ethics Committee. Work with human samples was carried out in accordance
with the Declaration of Helsinki (2000) of the World Medical Association.
This study was approved by the ethics committee of the Birmingham
and Black Country Comprehensive Local Research Network (LREC no.
10/H1202/40). All patients provided informed written consent. Samples
(n = 10) of colorectal carcinoma and colorectal polyps (n = 20), each matched
with normal colonic mucosa, were collected during either endoscopy or
surgery, and each tissue specimen was processed into mRNA and subjected
to qRT-PCR.
Mouse Colonies
Outbred mice segregating for the C57BL6J and S129 genomes (five genera-
tions C57Bl6J) were used from 4 to 8 weeks of age. The following alleles
were used: AH Cre (Ireland et al., 2004), Lgr5-EGFP-IREScreERT2 (Barker
et al., 2007), ApcMIN (Su et al., 1992), Apc580Sfl (Shibata et al., 1997), and
c-MYCfl (de Alboran et al., 2001). Only male mice were used in this study.
Iron Modulation
For luminal iron modulation, three diets were purchased from Harlan Labora-
tories UK: TD 80396 (IDD), TD 80394 (48 ppm added iron; CD), and TD 08496Cell Reports 2, 270–282, August 30, 2012 ª2012 The Authors 279
(CID). Male ApcMIN/+ and WT littermates were placed on the respective diet at
weaning (30 days of age) and were aged to a time point of 80 days of age.
Mice on the CID were taken due to illness at 60 days of age. To ensure that
the diets had no adverse effects, three WT mice from each group were kept
on each diet for 3 months. For systemic iron modulation, male ApcMIN/+ and
WT littermates were injected with IDex (CosmoFer 50 mg/ml; Pharmacosmos,
Holbaek, Denmark) or DFO (desferrioxaminemesilate 500mg;Mayne Pharma,
Warwickshire, UK) from weaning up to 80 days of age. IDex was administered
subcutaneously (subcut) at 50 mg per dose on 2 consecutive days at the start
of the treatment and once a month subsequently to keep the systemic iron
levels high. DFO 200 mg/kg was injected intraperitoneally (i.p.) daily for the
duration of the treatment to ensure effective systemic iron chelation. A
combined IDD and IDex treatment was also administered from weaning,
with mice receiving their first IDex injection the day they were put on the
IDD. The IDex treatment regime was continued as above while mice were
kept on the IDD until the 80 day time point.Gene Deletion In Vivo
Adult male mice (6–8 weeks of age) were put on the IDD or CID for 2 weeks
before genemanipulation to ensure diet acclimatization. For the survival study,
Lgr5creERT2+ Apcfl/flmice on IDD, CD, or CID were injected with a single dose
of 3 mg tamoxifen (Sigma, Dorset, UK) i.p. and aged until they showed signs of
illness. For time-point experiments, Lgr5creERT2+ Apcfl/flmice on the IDD, CD,
or CID were injected for 4 consecutive days with 3 mg (day 0), 2 mg (day 1),
2 mg (day 2), and 2 mg (day 3) tamoxifen i.p., and were taken at day 15
post-induction. AHCre+ Apcfl/fl mice on IDD, CD, or CID were injected 3 times
in 1 day with 80 mg/kg beta naphthoflavone (Sigma) i.p. and taken at day 4
post-induction. AHCre+ Apcfl/fl, AHCre+ c-MYCfl/fl, and AHCre+ Apcfl/fl
c-MYCfl/fl mice on the CD were injected 3 times in 1 day with 80 mg/kg beta
naphthoflavone i.p. and taken at day 4 post-induction.Tumor Scoring
When ApcMIN/+mice reached the 80-day time point, they were culled, and the
intestine and colon were removed and scored for tumors on whole mount.
WT littermates on the respective diets were also assessed for tumors. For
the ApcMIN/+ mice on CID (taken at 60 days of age), this was not possible
due to the small size of the tumors, so instead their tumors were assessed
on hematoxylin and eosin (H&E)-stained sections. The tumors were counted
in the first 10 cm of intestine near the stomach. As controls, a separate cohort
of ApcMIN/+ mice on CD was culled at the same time point of 60 days and
assessed for tumors in the same manner. For the Lgr5creERT2+ Apcfl/fl mice
day 15 experiments, lesions were scored off sections stained for b-catenin
(anti-b-catenin mouse monoclonal, 1:50; Transduction Labs, Oxford, UK). A
strip of 10 cm of intestine taken from the same position was scored for each
mouse (three versus three mice). A lesion was considered as R10 cells
clumped together and displaying nuclear b-catenin. This was done to distin-
guish lesions from individual cells positive for nuclear b-catenin found at the
bottom of the crypt. To measure the size of the lesions, the total number of
nuclear b-catenin-positive cells was counted.Assaying Apoptosis and Mitosis
The apoptotic and mitotic indexes were scored from H&E sections as
previously described (Sansom et al., 2004). For the AHCre+ Apcfl/fl day 4
experiments, 25 full crypts were scored from at least three mice of each
genotype. For the Lgr5creERT2+ Apcfl/fl survival cohorts, five mice were
chosen at random for each diet (IDD, CD, and CID) and five tumors were
scored per mouse. All of the cells in one tumor were included in the count.In Vivo Imaging
In vivo imaging of GFP fluorescence within intestinal tissue was performed as
follows: intestines were flushed with PBS, opened longitudinally, and imaged
using the Olympus OV100 molecular imaging system (Olympus, Southend-
on-Sea, UK). In Lgr5creERT2+ Apcfl/fl mice, the Lgr5-EGFP-IREScreERT2
construct drives the expression of GFP in cells that express the LGR5 stem
cell marker (Barker et al., 2007).280 Cell Reports 2, 270–282, August 30, 2012 ª2012 The AuthorsCell Culture
The human colorectal cell lines SW480 and RKOwere selected as examples of
lineages containing mutant and WT Apc molecule respectively and were both
routinely cultured in Dulbecco’s modified eagles medium (GIBCO, USA) with
10% fetal calf serum supplemented with 1% nonessential amino acids, 100
units/ml penicillin and 0.1mg/ml streptomycin. For iron loading experiments
cells were challenged upon reaching 70% confluence with either growth
medium alone (control) or iron loaded medium (growth medium supplemented
with 100 mM FeSO4 and 10 mM sodium ascorbate) for 24 hr and cellular iron
loading assessed as previously described (Whitnall et al., 2006).
c-Myc Overexpressing Cell Line
RKO cells were transiently transfected with a c-Myc ER construct (pCNDA3.1-
MYCER, a kind gift from Stella Pelengaris, University of Warwick), and 24 hr
later some of these cells were treated with 100 nM 4-hydroxytamoxifen
(4-OHT) for a further 48 hr. The cells were then lysed and processed into
mRNA and protein.
Western Blotting
Western blotting was performed as described previously, with antibodies
to c-Myc (C-20, 1:200 dilution; Autogen Bioclear, UK), TfR1 (1:1,000
dilution; Zymed Laboratories), DMT1 (1:1,000 dilution; a kind gift from Prof.
G. Anderson, University of Brisbane), ferritin (1:2500 dilution; Sigma), and
b-actin (C4, 1:1,000 dilution; Autogen Bioclear, Calne, UK).
Statistics
In Vitro Experiments
Statistical significance was calculated by use of the unpaired Student’s t test.
All analyses were performed using SPSS version 10.0 (SPSS, Chicago). Signif-
icance was accepted at p < 0.05. The data presented are the mean of three
independent experiments, each performed in triplicate.
In Vivo Experiments
Statistical significance for intestinal tumor scoring (tumor number, size, and
burden) was calculated using the nonparametric Mann-Whitney test. For
each group, three or more mice were used for comparison. For analysis of
survival cohorts, the Kaplan-Meier estimator was used together with the
logrank hypothesis test. For all tests, significance was accepted at p < 0.05.
Further methods can be found in Extended Experimental Procedures.
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